2733-41-7

Basic information

• Product Name: P-NITROBENZAZIDE
• Synonyms: 4-nitro-benzoylazid;P-NITROBENZOYL AZIDE;P-NITROBENZAZIDE;4-NITROBENZOYL AZIDE;azido-(4-nitrophenyl)methanone
• CAS NO: 2733-41-7
• Molecular Formula: C₇H₄N₄O₃
• Molecular Weight: 192.13
• EINECS: 220-351-5
• Mol File: 2733-41-7.mol
• Article Data: 53

Chemical Properties

• Melting Point: 72°C
• Boiling Point: 328.09°C (rough estimate)
• Appearance: /
• Density: 1.5614 (rough estimate)
• Refractive Index: 1.6700 (estimate)
• CAS DataBase Reference: P-NITROBENZAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: P-NITROBENZAZIDE(2733-41-7)
• EPA Substance Registry System: P-NITROBENZAZIDE(2733-41-7)

Safety Data

• Hazard Codes: F,Xn
• Statements: 2-11-20/22-36/37/38
• Safety Statements: 7/9-16-26-33
• Hazardous Substances Data: 2733-41-7(Hazardous Substances Data)

Usage

General Description

P-NITROBENZAZIDE is a chemical compound used as a high-performance initiator in explosives. It is a primary explosive and a strong oxidizing agent, making it valuable for its ability to rapidly and efficiently initiate explosive reactions. P-NITROBENZAZIDE is highly sensitive to heat, shock, and friction and can explode under certain conditions. Due to its hazardous nature, strict safety protocols and handling procedures are required when working with this chemical. It is primarily used in pyrotechnics and aerospace applications, especially in the ignition of airbags and seatbelt pretensioners.

InChI:InChI=1/C7H5N4O3/c8-10-9-7(12)5-1-3-6(4-2-5)11(13)14/h1-4,8H/q+1

Upstream product

• 6415-38-9 benzenediazonium sulphate 
• 636-97-5 N-amino-(4-nitrophenyl)carboxamide 
• 555-16-8 4-nitrobenzaldehdye 
• 7622-07-3 2,4-dinitrophenyl p-nitrobenzoate 
• 619-73-8 4-nitrobenzyl chloride 
• 619-50-1 4-nitrobenzoic acid methyl ester 
• 636-98-6 p-nitrobenzene iodide 
• 50-00-0 formaldehyd 
• 201230-82-2 carbon monoxide 
• 4231-71-4 1H-1,2,3-benzotriazol-1-yl-4-nitrophenylmethanone 
• 62-23-7 4-nitro-benzoic acid 
• 15922-01-7 potassium 4-nitrobenzoate 
• 21566-36-9 2,2-dibromo-1-(4-nitro-phenyl)-ethanone 
• 122-04-3 4-nitro-benzoyl chloride 

Downstream Products

• 50686-12-9 (4-nitro-phenyl)-carbamic acid p-tolyl ester 
• 2621-73-0 ethyl 4-nitrophenylcarbamate 
• 50686-15-2 (4-nitro-phenyl)-carbamic acid-(4-iodo-phenyl ester) 
• 50882-32-1 (4-nitro-phenyl)-carbamic acid-(3-nitro-phenyl ester) 
• 587-90-6 bis-N,N'-(4-nitrophenyl)urea 
• 76875-87-1 2-piperidinoethyl N-(4-nitrophenyl)carbamate 
• 6034-05-5 (4-nitro-phenyl)-carbamic acid-(2-diethylamino-ethyl ester) 
• 100-28-7 4-Nitrophenyl isocyanate 
• 104-04-1 N-(4-Nitrophenyl)acetamide 

Relevant articles and documents

Mechanochemical reactions studied by in situ Raman spectroscopy: Base catalysis in liquid-assisted grinding

In situ Raman spectroscopy was employed to study the course of a mechanochemical nucleophilic substitution on a carbonyl group. We describe evidence of base catalysis, akin to catalysis in solution, achieved by liquid-assisted grinding.

An Improved Synthesis of Polyfunctional Acyl Azides in PEG 400

-

Discovery of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido) phenylurea-based thymidylate synthase (TS) inhibitor as a novel multi-effects antitumor drugs with minimal toxicity

Thymidylate synthase (TS) is a hot target for tumor chemotherapy, and its inhibitors are an essential direction for anti-tumor drug research. To our knowledge, currently, there are no reported thymidylate synthase inhibitors that could inhibit cancer cell migration. Therefore, for optimal therapeutic purposes, combines our previous reports and findings, we hope to obtain a multi-effects inhibitor. This study according to the principle of flattening we designed and synthesized 18 of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido)phenyl urea derivatives as multi-effects inhibitors. The biological evaluation results showed that target compounds could significantly inhibit the hTS enzyme, BRaf kinase and EGFR kinase activity in vitro, and most of the compounds had excellent anti-cell viability for six cancer cell lines. Notably, the candidate compound L14e (IC50 = 0.67 μM) had the superior anti-cell viability and safety to A549 and H460 cells compared with pemetrexed. Further studies had shown that L14e could cause G1/S phase arrest then induce intrinsic apoptosis. Transwell, western blot, and tube formation results proved that L14e could inhibit the activation of the EGFR signaling pathway, then ultimately achieve the purpose of inhibiting cancer cell migration and angiogenesis in cancer tissues. Furthermore, in vivo pharmacology evaluations of L14e showed significant antitumor activity in A549 cells xenografts with minimal toxicity. All of these results demonstrated that the L14e has the potential for drug discovery as a multi-effects inhibitor and provides a new reference for clinical treatment of non-small cell lung cancer.